14:0 PE-DTPA (Gd)


CAT No.# CS-CC-00046
Category Lipids
CAS 827020-81-5
Stock Status

(Available within 3-5 days)

Product maybe under re-certification or re-stock. Enquire now to know exact date of delivery and pricing.
Molecular Weight 1199.47
Molecular Formula C47H90GdN6O17P
Synonyms: diammonium gadolinium(III) (R)-2,2'-(13-(((2,3-bis(tetradecanoyloxy)propoxy)oxidophosphoryl)oxy)-1-carboxylato-2-(carboxylatomethyl)-9-oxo-2,5,8,11-tetraazatridecane-5,8-diyl)diacetate
Application Notes: Lipid nanoparticles containing DMPE-DTPA(Gd) provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance.
References: Barazza, A., C. Blachford, O. Even-Or, V.A. Joaquin, K.C. Briley-Saebo, W. Chen, X.C. Jiang, W.J. Mulder, D.P. Cormode, Z.A. Fayad, and E.A. Fisher. (2013). The Complex Fate in Plasma of Gadolinium Incorporated into High-Density Lipoproteins Used for Magn??%?
Shipping: Free Shipping for worldwide on order above 2000 USD
14:0 PE-DTPA (Gd) Worldwide Suppliers of 14:0 PE-DTPA (Gd) Lipids Clearsynth CS-CC-00046

Product rating: 9 14:0 PE-DTPA (Gd) based on 20 ratings

  1. Lipids
  2. 14:0 PE-DTPA (Gd)

PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Lauroside D
4. Triazolam 13C D3
5. Icatibant impurity 1
7. 0.1% TFA in Water ULC-MS
8. Metamizole EP Impurity C HCl
9. Silodosin Metabolite D4
10. Silodosin Metabolite
11. 2-Phenoxymethanesulfonanilide
12. Nimesulide EP Impurity A
13. Acetone HPLC
14. Riluzole (1604337)
15. Pheniramine impurity B
16. Palbociclib N-Glucuronide
17. Carpropamid
18. Olmesartan N1-Trityl Impurity
19. Aripiprazole (1042634)
20. 2-(p-Tolyl)pyrimidine

This page contains information about 14:0 PE-DTPA (Gd) Cas 827020-81-5 and its Lipids.

14:0 PE-DTPA (Gd) 14:0 PE-DTPA (Gd) Worldwide Suppliers of 14:0 PE-DTPA (Gd) Lipids Clearsynth 827020-81-5

"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."